MarketPulse
I

$IMMP

17 articles found
1 positive
16 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Immutep Faces Class Action Over $IMMP Trial Failure; Investors Have Days to Join Lawsuit

Immutep faces class action lawsuit alleging investor deception over TACTI-004 trial failure. Stock plunged 83% after March discontinuation announcement, despite positive January guidance. Lead plaintiff deadline: July 6, 2026.
IMMPclass action lawsuitmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Collapses 82.6% After Failed Phase III Trial, Triggering Class Action

Immutep shares plummet 82.6% after discontinuing Phase III trial for eftilagimod alfa due to futility, triggering class action investigation by Rosen Law Firm.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Disc Medicine Stock Plunges 22% After FDA Rejection; Class Action Investigation Underway

Disc Medicine ($IRON) shares tumbled 22% following FDA rejection of its bitopertin program. Law firm investigates potential securities violations and shareholder losses.
IRONNUAINUAIWIMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Plummets 82.6% After Failed Phase III Trial for Cancer Drug

Immutep stock crashed 82.6% after discontinuing a Phase III trial; Rosen Law Firm investigating potential securities fraud claims for shareholders.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··The Rosen Law Firm

Immutep Stock Collapses 82.6% After Failed Phase III Trial Halts Development

Immutep shares plummet 82.6% after independent committee halts Phase III trial for lead candidate eftilagimod alfa due to futility.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Collapses 82.6% After Failed Cancer Trial, Triggering Class Action

Immutep's $IMMP shares plummeted after discontinuing Phase III trial for cancer drug. Rosen Law Firm investigates potential securities fraud claims.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··The Rosen Law Firm

Immutep Stock Plummets 82.6% After Failed Phase III Trial for Lead Cancer Drug

Immutep's stock crashed to $0.48 after its independent monitoring committee halted the TACTI-004 Phase III trial for eftilagimod alfa due to futility, prompting legal investigation.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Immutep Limited

Immutep Wins FDA Orphan Drug Nod for Sarcoma Treatment Eftilagimod Alfa

Immutep gains FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma, with Phase II trial results exceeding efficacy targets by 47%.
MRKIMMPFDA approvalorphan drug designation
GlobeNewswire Inc.GlobeNewswire Inc.··The Rosen Law Firm

America's Car-Mart Stock Plunges 18.2% on Disappointing Losses; Securities Probe Launched

America's Car-Mart ($CRMT) stock fell 18.2% after disappointing earnings. Securities lawyers are investigating alleged misleading disclosures and preparing class action lawsuits.
PFSICRMTIMMPsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Plummets 82.6% on Failed Clinical Trial; Class Action Probe Launched

Immutep's $IMMP stock crashed 82.6% after discontinuing Phase III trial for lead drug candidate. Rosen Law Firm investigating potential securities violations and class action claims.
IMMPsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Immutep Stock Crashes 82% After Failed Phase III Trial; Law Firm Launches Investor Investigation

Immutep stock collapsed 82% after Phase III trial failure. Law firm investigates potential securities fraud regarding disclosure timing and adequacy.
IMMPsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Rosen Law Firm

Immutep's Failed Trial Triggers Stock Collapse as Rosen Law Firm Launches Securities Investigation

Immutep's failed Phase III trial triggered an 82.6% stock collapse, prompting a securities investigation by The Rosen Law Firm into potential shareholder claims.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Plummets 82.6% After Failed Phase III Trial; Class Action Lawsuit Looms

Immutep's stock crashed after discontinuing Phase III TACTI-004 trial for eftilagimod alfa due to futility, prompting securities litigation against the biotech firm.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

PomDoctor Securities Class Action: April 7 Deadline Looms for Defrauded Investors

Rosen Law Firm urges PomDoctor Ltd. investors with losses exceeding $100K to file securities claims by April 7, 2026, alleging fraud via social media misinformation and insider selling.
RAREPOMIMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Plunges 82.6% After Failed Phase III Trial, Sparking Class Action

Immutep's $IMMP stock crashed after trial discontinuation announcement. Rosen Law Firm investigates securities claims for investor losses.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Plummets 82.6% After Failed Phase III Trial, Sparking Lawsuit

Immutep's $IMMP stock crashed following discontinued Phase III trial for eftilagimod alfa. Rosen Law Firm launches investigation into potential securities claims and class action lawsuit.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson Fistel, Pllp

Horizon Technology Finance Stock Crashes 23% as Securities Investigation Looms

Johnson Fistel investigates potential securities fraud at Horizon Technology Finance after stock plummeted 23% following disappointing Q4 2025 earnings guidance.
HRZNHTFCGIIIIMMPsecurities fraudclass action lawsuit